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Abstract
Antibiotics alter the composition, and numbers of the normal gastrointestinal (GI) microflora,
providing Clostridium difficile, a spore forming, Gram-positive bacillus, the opportunity to
colonize the GI tract1,2,3. C. difficile is the leading cause of hospital-acquired diarrhea, resulting
in death of 1% to 2% of infected patients2,3. It is responsible for GI diseases ranging from
antibiotic-associated diarrhea to the more severe pseudomembranous colitis4. In addition to
having resistance to various antimicrobial drugs, the treatment of C. difficile infections with
specific antibiotics such as metronidazole often results in relapse, resistance development, and
further disruption of the GI microflora4. Thus, the establishment of an alternative method to
combat C. difficile is crucial. Previous studies show that Lactobacillus salivarius, a promising
probiotic organism, produces a potent two-peptide bacteriocin that hinders C. difficile growth5.
Previous research indicates that L. salivarius is effective in reducing C. difficile cell count,
although none investigated the effect of L. salivarius on the two major virulence factors -
toxin A (TcdA) and toxin B (TcdB)6. To this end, this investigation aimed to investigate the
influence of L. salivarius on TcdA and Tcd B production. L. salivarius and C. difficile were
co-cultured, growth curves of C. difficile, L. salivarius, and the co-culture were generated, and
cell-free supernatants at various stages were examined to quantify TcdA and TcdB concentrations.
Although there was no noticeable decrease in TcdA and TcdB concentration in the co-culture,
C. difficile toxin production was observed to be more multi-phasic in co-culture. Moreover,
co-culturing L. salivarius with C. difficile significantly hindered C. difficile growth, confirming
previous results. Taken together, the data suggests that the presence of L. salivarius enhances
C. difficile toxin production per cell, implying the potential dangers of initiating clinical trials
without a comprehensive investigation of the effects of probiotics and the production of C.
difficile virulence factors.
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